Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results
Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Badros, Jacob P. Laubach, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Dharminder Chauhan, Nancy K. Levin, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results. , 180(1), DOI: https://doi.org/10.1111/bjh.14987.
Article289 days agoPmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
Andrew Spencer, Simon J. Harrison, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Kenneth C. Anderson, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. , 128(22), DOI: https://doi.org/10.1182/blood.v128.22.3326.3326.
Article289 days agoPhase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
Andrew Spencer, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Simon J. Harrison, Amit Khot, Dharminder Chauhan, Kenneth C. Anderson, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2015). Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4220.4220.
Article289 days agoIsatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Peter O’Gorman, Jacob P. Laubach, Ruth Clifford, Clifton C. Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Ølholm Vase, Keith W. Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emelia Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah J. Beaton, C. Prior, C. Piper, Bindu Krishnanivas, Emily J. Simpson, Ebrahim Karimi, Marissa Davis, Lourdes del Rosario McAlester, Amanda Allen, Paul Richardson (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-4030.
Article34 days agoIsatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Peter O’Gorman, Jacob P. Laubach, Ruth Clifford, Clifton C. Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Ølholm Vase, Keith W. Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emelia Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah J. Beaton, C. Prior, C. Piper, Bindu Krishnanivas, Emily J. Simpson, Ebrahim Karimi, Marissa Davis, Lourdes del Rosario McAlester, Amanda Allen, Paul Richardson (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-4030.
Article34 days ago